

WHAT CLINICIANS WANT TO KNOW:

Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Hematologic Cancers

Select Publications

Multiple Myeloma

- Broyl A et al. **Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial.** *Lancet Oncol* 2010;11(11):1057-65. **Abstract**
- Cavallo F et al. **Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.** *Leukemia* 2011;25(10):1627-31. **Abstract**
- Dimopoulos MA et al. **Lenalidomide: An update on evidence from clinical trials.** *Blood Rev* 2010;24(Suppl 1):21-6. **Abstract**
- Jain S et al. **Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.** *Core Evid* 2011;6:43-57. **Abstract**
- Lacy MQ et al. **Pomalidomide therapy for multiple myeloma and myelofibrosis: An update.** *Leuk Lymphoma* 2011;52(4):560-6. **Abstract**
- Mateos MV et al. **Subcutaneous bortezomib: A step towards optimised drug use.** *Lancet Oncol* 2011;12(5):410-1. **Abstract**
- Moreau P et al. **New developments in conditioning regimens before auto-SCT in multiple myeloma.** *Bone Marrow Transplant* 2011;46(7):911-5. **Abstract**
- Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol* 2011;12(5):431-40. **Abstract**
- Parrish C et al. **The role of high dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma refractory to initial induction therapy.** *Proc ASH* 2010;Abstract 1341.
- Rajkumar SV et al. **Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.** *Am J Hematol* 2011;86(1):57-65. **Abstract**
- Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86. **Abstract**
- Richardson PG et al. **Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.** *Lancet Oncol* 2010;11(11):1014-6. **Abstract**
- Zeldis JB et al. **Lenalidomide in multiple myeloma: Current role and future directions.** *Expert Opin Pharmacother* 2010;11(5):829-42. **Abstract**

Chronic Lymphocytic Leukemia

- Badoux XC et al. **Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.** *Blood* 2011;118(13):3489-98. **Abstract**
- Bryan J, Borthakur G. **Role of rituximab in first-line treatment of chronic lymphocytic leukemia.** *Ther Clin Risk Manag* 2010;7:1-11. **Abstract**

Ferrajoli A et al. **Treatment of younger patients with chronic lymphocytic leukemia.** *Hematology Am Soc Hematol Educ Program* 2010;2010:82-9. **Abstract**

Gribben JG et al. **Update on therapy of chronic lymphocytic leukemia.** *J Clin Oncol* 2011;29(5):544-50. **Abstract**

Jamshed S et al. **Role of bendamustine in the treatment of chronic lymphocytic leukemia.** *Onco Targets Ther* 2009;2:43-9. **Abstract**

Malhotra P et al. **Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: Analysis after a minimum follow-up of 5 years.** *Leuk Lymphoma* 2008;49(9):1724-30. **Abstract**

O'Brien S et al. **Maintenance therapy for B-chronic lymphocytic leukemia.** *Clin Adv Hematol Oncol* 2011;9(1):22-31. **Abstract**

Chronic Myeloid Leukemia

Cervantes F, Mauro M. **Practical management of patients with chronic myeloid leukemia.** *Cancer* 2011;117(19):4343-54. **Abstract**

Jabbour E et al. **Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response?** *J Clin Oncol* 2011;[Epub ahead of print]. **Abstract**

Jabbour E et al. **Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: What is the optimal strategy?** *Mayo Clin Proc* 2009;84(2):161-9. **Abstract**

Mauro MJ, Maziarz RT. **Stem cell transplantation in patients with chronic myelogenous leukemia: When should it be used?** *Mayo Clin Proc* 2006;81(3):404-16. **Abstract**

O'Brien S et al. **NCCN Task Force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.** *J Natl Compr Canc Netw* 2011;9(Suppl 2):1-25. **Abstract**

Shami PJ, Deininger M. **Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: The role of second-generation BCR-ABL inhibitors as first-line therapy.** *Leukemia* 2011;[Epub ahead of print]. **Abstract**

Follicular Lymphoma

Freedman A. **Follicular lymphoma: 2011 update on diagnosis and management.** *Am J Hematol* 2011;86(9):768-75. **Abstract**

Hoppe RT. **Treatment strategies in limited stage follicular NHL.** *Best Pract Res Clin Haematol* 2011;24(2):179-86. **Abstract**

Rummel MJ et al. **Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).** *Proc ASH* 2009;Abstract 405.

Tuccori M et al. **Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.** *Oncologist* 2010;15(11):1214-9. **Abstract**

Diffuse Large B-Cell Lymphoma

Corazzelli G et al. **A phase II study of R-COMP14 in elderly patients with high-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high "life threat" impact cardiopathy.** *Proc ASCO* 2011;Abstract 8058.

Tilly H et al. **Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2010;21(Suppl 5):v172-4. **Abstract**

Mantle-Cell Lymphoma

Budde LE et al. **Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.** *J Clin Oncol* 2011;29(22):3023-9. **Abstract**

Dreyling M et al. **Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th annual conference of the European Mantle Cell Lymphoma Network.** *Leuk Lymphoma* 2011;[Epub ahead of print]. **Abstract**

Kluin-Nelemans HC et al. **Treatment of elderly patients with mantle cell lymphoma.** *Semin Hematol* 2011;48(3):208-13. **Abstract**

Ondrejka SL et al. **Indolent mantle cell leukemia: A clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis.** *Haematologica* 2011;96(8):1121-7. **Abstract**

Rummel M. **Reassessing the standard of care in indolent lymphoma: A clinical update to improve clinical practice.** *J Natl Compr Canc Netw* 2010;8(Suppl 6):1-14. **Abstract**

Williams ME et al. **Management of mantle cell lymphoma: Key challenges and next steps.** *Clin Lymphoma Myeloma Leuk* 2010;10(5):336-46. **Abstract**

Peripheral and Cutaneous T-Cell Lymphomas

Hui J et al. **Pralatrexate: A novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.** *J Oncol Pharm Pract* 2011;[Epub ahead of print]. **Abstract**

O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol* 2011;29(9):1182-9. **Abstract**

O'Connor OA. **Novel agents in development for peripheral T-cell lymphoma.** *Semin Hematol* 2010;47(Suppl 1):11-4. **Abstract**

Reimer P. **Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas.** *Adv Hematol* 2010;2010:320624. **Abstract**

Roncolato F et al. **Targeted molecular therapy in peripheral T-cell lymphomas.** *Expert Rev Hematol* 2011;4(5):551-62. **Abstract**

Wilcox RA. **Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.** *Am J Hematol* 2011;86(11):928-48. **Abstract**

Wong HK et al. **Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).** *Br J Haematol* 2011;155(2):150-66. **Abstract**